Back to top

Image: Bigstock

3 Stocks Rallying After Strong Q3 Earnings and Raised Guidance

Key Takeaways

  • The Q3 earnings season is winding down, with HAS, TGTX, and IDXX all knocking it out of the park.
  • Each of the trio raised guidance, with each seeing a strong post-earnings reaction.
  • Earnings estimate revisions remain bullish, providing a favorable near-term momentum setup.

The Q3 earnings cycle is winding down at this point, with several companies delivering strong results and seeing favorable post-earnings reactions as a result.

Notable winners in this earnings cycle include Hasbro (HAS - Free Report) , IDEXX Laboratories (IDXX - Free Report) , and TG Therapeutics (TGTX - Free Report) , all of which also raised their guidance. The trio has also shown relative strength against the broader market over the past month, outperforming amid the recent volatility spike.

Zacks Investment Research
Image Source: Zacks Investment Research

Hasbro Reports Strong Segment Strength

Hasbro, a current Zacks Rank #1 (Strong Buy), designs, manufactures, and markets games, toys, and licensed products, offering traditional, high-tech, and digital play experiences. Its latest results showed nice positivity, with revenue climbing 15% YoY to roughly $1.6 billion and adjusted earnings soaring 70% to $2.90 per share, comfortably exceeding expectations.

Zacks Investment Research
Image Source: Zacks Investment Research

The Wizards of the Coast and Digital Gaming segment led the strong performance, with revenue jumping 31% YoY. Magic: The Gathering remained the biggest highlight, with quarterly sales surpassing $600 million for the first time and up 34% YoY.

Zacks Investment Research
Image Source: Zacks Investment Research

Given the strong results, management raised its FY26 revenue growth outlook and doubled its share repurchase target for the year, further boosting sentiment. Shares also reflect a solid opportunity from an income-focused standpoint, currently yielding a solid 2.3% annually.

Growth Outlook Remains Strong for IDXX

IDEXX Laboratories, a current Zacks Rank #2 (Buy), provides diagnostic testing products, software, and other solutions primarily focused on veterinary healthcare. Shares surged after its Q3 release, with EPS of $4.01 up 18% YoY and revenue up 10% to $1.2 billion.

Zacks Investment Research
Image Source: Zacks Investment Research

Companion Animal Group Diagnostics recurring revenue was a big highlight, climbing 11% YoY thanks to higher testing volumes and continued adoption of its diagnostic offerings. The overall solid results led management to raise its FY26 revenue guidance into a range of $4.74 – $4.77 billion, with EPS now expected between $14.96 – $15.16 per share.

Earnings estimates have moved higher nearly across the board following the updated outlook, with earnings on track to grow by double digits in its current and next fiscal years.

Zacks Investment Research
Image Source: Zacks Investment Research

TGTX Shares Hover at All-Time Highs

TG Therapeutics is a commercial-stage biotechnology company focused on treatments for B-cell diseases. Like those above, TGTX delivered strong Q3 results, with revenue jumping 61% YoY to $260 million, with EPS of $0.35 exceeding the $0.28 Zacks Consensus estimate.

The company’s EPS outlook remains highly bullish, with estimates rising across all timeframes.

Zacks Investment Research
Image Source: Zacks Investment Research

BRIUMVI, its treatment for relapsing forms of multiple sclerosis, continues to reflect the primary growth driver, with U.S. net product sales climbing 52% YoY to $232.6 million thanks to increasing physician adoption and a growing patient base.

Given the strength, management raised its FY26 global revenue guidance to approximately $1 billion from $950 million previously. Its outlook for U.S. BRIUMVI sales was also raised into a range of $915 – $920 million.

Zacks Investment Research
Image Source: Zacks Investment Research

Bottom Line

The Q3 earnings season has delivered several big winners, with Hasbro (HAS - Free Report) , IDEXX Laboratories (IDXX - Free Report) , and TG Therapeutics (TGTX - Free Report) all posting strong results that have helped drive relative strength over the last month, with each raising guidance in one way or another.

Published in